The board of directors of International Genius Company announced that Dr. He Xiaobin (?Dr. He?) has been appointed as an executive director and chief economist with effect from 25 April 2024. Dr. He Xiaobin, male, aged 61, holds a doctoral degree in economics and is a senior economist. He has more than 30 years of working experience in futures investment and corporate compliance, and has extensive financial knowledge and management experience.

Dr. He served as the director of the Futures Supervision Division of the Shanghai Securities Regulatory Bureau of the China Securities Regulatory Commission, and the deputy director of the Resource and Energy Division of the Shanghai Municipal Planning Committee. Dr. He also served as the chairman of Guotai Junan Futures, the secretary to the board of directors of Guotai Junan Securities, the president of Guotai Junan Asset Management, the chief economist of Huaxin Securities and the chairman of Huaxin Futures, a director of the China Chief Economist Forum, a member of the Chief Economist Committee of the Securities Association of China, and a director of Shenergy Co. Ltd. Dr. He is entitled to special allowance from the State Council of the People's Republic of China, was selected as one of the top ten financial industry leaders in Shanghai, and was an adjunct professor at Shanghai Jiao Tong University and Tongji University.

Dr. He was an independent non-executive director of Target Insurance (Holdings) Limited, from March 2023 to January 2024. The Board announced that Dr. Lin Feng (?Dr. Lin?) has tendered his resignation as an executive director of the Company with effect from 25 April 2024. Upon the Resignation of Dr. Lin, he would also cease to act as an authorised representative of the Company required under Rule 3.05 of the Rules Governing the Listing of Securities on the Stock Exchange, the chairman of risk management committee and a member of each of the executive committee and the nomination committee of the Company; and Ms. Sun Qiuzhen (?Ms. Sun?) has tendered her resignation as a non-executive director of the Company with effect from 25 April 2024.

Following the resignation of Dr. Lin, Dr. He has been appointed as the Authorised Representative with effect from 25 April 2024. The Board also announced that, with effect from 25 April 2024, Dr. He has been appointed as the chairman of the risk management committee and a member of each of the executive committee and nomination committee of the Company.